Videos

Aerie Pharmaceuticals With Two ROCK Inhibitors In Development

By Tom Salemi | November 7, 2014

Publicly traded Aerie Pharmaceuticals Inc. has two Rho kinase inhibitors, or ROCK inhibitors, in development, CEO Vicente Anido, Jr, PhD, reported Rhopressa which is in phase…

Read More

ONL Therapeutics Develops Novel Mechanism To Attack Fas Receptor Apoptosis

By Tom Salemi | November 7, 2014

ONL Therapeutics Inc. is developing Met12, a small peptide inhibitor that uses a novel mechanism to attack Fas receptor apoptosis, which has a key role…

Read More

Kala Pharmaceuticals Offers Glimpse Into Preclinical Pipeline

By Tom Salemi | November 7, 2014

Kala Pharmaceutical Inc. is moving its proprietary Lotoprednol Etaobnate Mucus Penetrating Particle (LE-MPP) platform through a host of trials, Interim President and CBO Charlie McDermott…

Read More

Translatum Medicus Developing Option To Treat Dry AMD

By Tom Salemi | November 7, 2014

Clinicians have few treatment options for dry AMD, but Translatum Medicus Inc., is working on an agent, TMi-018, for such an indication. President and CSO…

Read More

Panoptes Developing Inhibitor For Local Treatments In Ocular Disease

By Tom Salemi | November 7, 2014

Panoptes Pharma GmhB is developing PP-001, a dihydroorotate dehydrogenase (DHODH) inhibitor for local treatments in ocular disease, Co-Founder and CEO Franz Obermayr, PhD, told the…

Read More

How Alcon and Google Could Change The Contact Lens

By Tom Salemi | October 28, 2014

Moderator: Gilbert H. Kliman, MD Dr. Gil Kliman leads the medical device investment team at InterWest Partners and invests in a broad array of healthcare…

Read More

WaveTec Vision Systems

By Tom Salemi | April 24, 2014

WaveTec Vision® Systems, Inc. is a privately-held ophthalmic medical device company and is the proven leader in intraoperative wavefront technology. The company is focused on…

Read More

pSivida

By Tom Salemi | April 24, 2014

Paul Ashton talks about the innovation within pSivida and its early stage work on proteins. pSivida has developed 3 of the 4 sustained delivery systems…

Read More

PowerVision

By Tom Salemi | April 24, 2014

Barry Cheskin discusses PowerVision’s six month data on their pilot study and the beginning their CE mark study. Presenter: Barry Cheskin Barry Cheskin is Co-Founder,…

Read More

Panoptes Pharma

By Tom Salemi | April 24, 2014

Franz Obermayr gives a short overview of Panoptes Pharma founded only last year, covering only one of their developments: C0C01 for local treatment in ophthalmology. Presenter:…

Read More

Ocular Therapeutix

By Tom Salemi | April 24, 2014

Amar Sawhney gives us an update on what’s going on in Ocular Therapeutix, showing us an in depth look at their product pipeline and what…

Read More

EyeSonix

By Tom Salemi | April 24, 2014

Donald Schwartz talks about TUG, which is the only ultrasound treatment designed for all open angle glaucoma. Presenter: Donald Schwartz Donald Schwartz is a comprehensive…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.